FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2357-2359 December 11, 2003 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

What is all the noise about RNA silencing? And how does silencing, or impairing translation of target RNAs, help us develop effective therapies for chronic and acute liver diseases? As with many important advances in molecular medicine, the answer, once found, is elegantly simple. Deliver to cells a small duplex or hairpin RNA with sequences that match only those of your target, and let natural cellular mechanisms do the rest (Figure 1). Voila! Target RNA degradation and inhibit downstream expression. Unlike antisense-DNA–based approaches, inhibition by RNA silencing is highly efficient, because it takes advantage of endogenous cellular machinery . . . [Full Text of this Article]

Source Information

From the Department of Internal Medicine, University of Iowa, Iowa City.

This article has been cited by other articles:

• Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., Wessely, R. (2005). Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice. Circulation 111: 1583-1592 [Abstract] [Full Text]